Taiwan Bio Therapeutics Co., Ltd
Taiwan Bio Therapeutics Co., Ltd., regenerative medicine company, focuses on the development of new cell medicines. It offers medicines for degenerative diseases, cardiovascular diseases, diabetes complications, and autoimmune diseases. The company was founded in 2014 and is based in Taipei City, Taiwan.
Taiwan Bio Therapeutics Co., Ltd (6892) - Total Assets
Latest total assets as of June 2025: NT$1.29 Billion TWD
Based on the latest financial reports, Taiwan Bio Therapeutics Co., Ltd (6892) holds total assets worth NT$1.29 Billion TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Taiwan Bio Therapeutics Co., Ltd - Total Assets Trend (2020–2024)
This chart illustrates how Taiwan Bio Therapeutics Co., Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Taiwan Bio Therapeutics Co., Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Taiwan Bio Therapeutics Co., Ltd's total assets of NT$1.29 Billion consist of 53.4% current assets and 46.6% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 46.0% |
| Accounts Receivable | NT$39.87 Million | 2.7% |
| Inventory | NT$31.35 Million | 2.1% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$81.97 Million | 5.6% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Taiwan Bio Therapeutics Co., Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Taiwan Bio Therapeutics Co., Ltd's current assets represent 53.4% of total assets in 2024, an increase from 20.7% in 2020.
- Cash Position: Cash and equivalents constituted 46.0% of total assets in 2024, up from 18.3% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 0.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 5.6% of total assets.
Taiwan Bio Therapeutics Co., Ltd Competitors by Total Assets
Key competitors of Taiwan Bio Therapeutics Co., Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Taiwan Bio Therapeutics Co., Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Taiwan Bio Therapeutics Co., Ltd generates 0.07x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Taiwan Bio Therapeutics Co., Ltd is currently not profitable relative to its asset base.
Taiwan Bio Therapeutics Co., Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.15 | 8.53 | 5.38 |
| Quick Ratio | 7.66 | 7.67 | 4.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$545.28 Million | NT$ 472.84 Million | NT$ 247.82 Million |
Taiwan Bio Therapeutics Co., Ltd - Advanced Valuation Insights
This section examines the relationship between Taiwan Bio Therapeutics Co., Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.64 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 56.3% |
| Total Assets | NT$1.47 Billion |
| Market Capitalization | $8.06K USD |
Valuation Analysis
Below Book Valuation: The market values Taiwan Bio Therapeutics Co., Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Taiwan Bio Therapeutics Co., Ltd's assets grew by 56.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Taiwan Bio Therapeutics Co., Ltd (2020–2024)
The table below shows the annual total assets of Taiwan Bio Therapeutics Co., Ltd from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.47 Billion | +56.30% |
| 2023-12-31 | NT$941.76 Million | +8.12% |
| 2022-12-31 | NT$871.01 Million | +47.60% |
| 2021-12-31 | NT$590.13 Million | +195.61% |
| 2020-12-31 | NT$199.63 Million | -- |